Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ARCHIVE
ARCHIVE
- SUEVEY
August 8, 2011
- Pregabalin to Be Recommended as 1st-line Drug in New GLs for Peripheral Neuropathic Pain
August 8, 2011
- Takeda Resubmits NDA for DPP-4 Inhibitor in the US
August 8, 2011
- Takara Bio Announces TCR Gene Therapy Collaboration in China
August 8, 2011
- MIC to Test Electronic Prescribing System
August 8, 2011
- Korosho's New GLs Call For Use of IT to Distribute Safety Info.
August 8, 2011
- Takeda to Start Multinational PIII Trial for TAK-875 in FY2011
August 8, 2011
- R&D Spending Fell, Discontinued Clinical Trials Increased in 2010: Thomson Reuters
August 8, 2011
- Kyowa Kirin Files for PD Treatment KW-6500 in Japan
August 8, 2011
- Nippon Chemiphar Discontinues Development of NC-2300
August 8, 2011
- Eve No. 1 OTC Analgesic/Antipyretic Drug 3 Months in a Row
August 8, 2011
- R-Tech Ueno Discontinues PI Study of Hypotrichosis Drug in UK
August 8, 2011
- Marketing Expenses Up 1.5% to US$91 Bil. in 2010: CSD Survey
August 8, 2011
- Taiho's TAS-102 Prolongs OS in mCRC: JSMO Annual Meeting
August 8, 2011
- Oncology Products to Contribute to Astellas' Business from 2018 Onward: President Hatanaka
August 8, 2011
- Avastin's Efficacy in Combination with FOLFIRI for Colon Cancer Confirmed in Domestic PII Study
August 8, 2011
- Shionogi to Enter Chinese Market by Acquiring Local Company
August 8, 2011
- BioWa Licenses Potelligent Technology to arGEN-X
August 8, 2011
- Medipal, JCR Pharm. Announce Tie-up; Medipal to Invest in Drug Development
August 8, 2011
- Toyama Chemical to Construct New Pharmacology Research Lab
August 8, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…